Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced the appointment of Robert J. O'Neill to its Advisory Board. O'Neill served 16 years in the U.S. Navy, including eight years with the Naval Special Warfare Development Group (SEAL Team Six), and participated in more than 400 combat missions. He is also a New York Times best-selling author and an advocate for expanding veterans' access to emerging health treatments.
O'Neill will support Nutriband's executive team on strategy, growth, and execution as the company advances its pipeline of abuse-deterrent transdermal products, including AVERSA Fentanyl. According to the company, AVERSA Fentanyl would be the world's first and only abuse-deterrent fentanyl patch if approved. This appointment brings high-profile military and advocacy experience to Nutriband as it seeks to commercialize its lead product.
The addition of O'Neill to the Advisory Board could enhance Nutriband's strategic direction and visibility, particularly given his background in leadership and advocacy. His involvement may also help the company navigate regulatory and public perception challenges associated with opioid products. For investors, this development signals a potential strengthening of the company's management expertise as it pursues approval for AVERSA Fentanyl. For the broader healthcare industry, it highlights ongoing efforts to develop abuse-deterrent technologies that could reduce misuse and diversion of potent pain medications.
Nutriband's AVERSA technology is designed to be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating this technology. More information about Nutriband is available at www.nutriband.com. The latest news and updates relating to NTRB can be found in the company's newsroom at https://ibn.fm/NTRB.
The full press release can be viewed at https://ibn.fm/WuoNR. InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication, distributed the announcement. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
For more information about InvestorWire, visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
